Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Coloplast A/S is a Denmark-based company active within the healthcare sector. It is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The Company supplies products to hospitals, institutions as well as wholesalers and pharmacies.

  • Revenue in DKK (TTM)20.61bn
  • Net income in DKK4.75bn
  • Incorporated1957
  • Employees13.51k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
COLO B:CPH since
Atos Medical ABDeal completed08 Nov 202108 Nov 2021Deal completed-21.10%2.49bn
Data delayed at least 15 minutes, as of Aug 08 2022 12:40 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
GN Store Nord A/S15.52bn1.09bn35.56bn7.75k30.945.5014.762.298.388.38120.0447.090.69253.255.372,147,759.
Getinge AB19.45bn1.91bn40.16bn10.99k22.532.1612.502.069.799.7999.67102.140.60232.586.562,530,152.005.983.347.264.4548.9048.069.925.781.4028.170.160140.67-9.294.06-8.3133.59-10.3615.20
ConvaTec Group PLC15.17bn585.50m43.65bn10.03k74.133.7720.452.880.03270.03270.84680.64250.55863.116.10171,454.
Amplifon SpA15.08bn1.29bn51.19bn12.59k39.696.9716.983.400.76540.73998.944.360.594823.5811.09160,943.405.084.616.776.1224.8555.818.537.240.54429.960.616229.1029.5911.4564.6720.1212.6530.01
Demant A/S18.39bn2.51bn63.77bn18.12k25.848.33--3.4710.7110.7178.3133.220.7862.115.871,015,014.0010.818.8917.8014.4875.1375.2313.7511.630.503123.540.58690.0027.298.94124.1711.4911.83--
Smith & Nephew plc38.10bn3.63bn83.00bn18.00k23.022.1010.532.180.46840.46844.925.120.49560.80754.13235,102.904.726.695.908.0871.0372.549.5112.340.83567.990.349152.9014.302.2216.96-7.740.80335.28
Carl Zeiss Meditec AG12.91bn1.97bn90.53bn3.75k46.027.0074.567.012.962.9619.3919.430.73142.3410.80491,312.4011.228.5713.7910.5659.4056.5915.3411.342.708.770.106236.1523.318.6493.0619.1618.8116.47
Koninklijke Philips NV127.97bn3.00bn132.57bn78.83k46.251.2010.041.040.43313.2219.2916.630.55922.755.00219,915.801.323.591.835.0141.5045.572.365.640.704311.620.3514---0.9068-0.3072-38.65-5.050.18451.63
Straumann Holding AG15.37bn3.01bn156.09bn9.05k51.9813.7240.8610.152.482.4812.679.400.7332.075.99223,316.0014.4812.9117.5015.6276.1775.1619.7518.082.278.320.312133.3041.8017.12333.9111.5220.979.69
Coloplast A/S20.61bn4.75bn164.26bn13.51k37.2724.2329.567.9722.2622.2696.6634.240.81742.506.101,618,950.0018.8332.3550.5354.6168.7567.9523.0323.370.21361,096.170.743587.954.765.7614.968.9524.827.07
Sonova Holding AG25.58bn4.93bn165.12bn16.73k33.198.7124.836.4610.3610.3653.6439.460.58432.527.37201,033.9011.5310.5015.2413.5573.2371.8019.7317.470.828225.000.338433.6529.297.0214.2012.581.6513.85
Sartorius Stedim Biotech SA24.26bn4.77bn255.00bn11.94k53.4916.7042.9910.516.956.9535.3322.260.82551.978.72313,140.3016.1713.2921.8417.5852.7052.6219.5915.970.632913.170.25622.5351.1422.3823.3621.9532.3724.57
Siemens Healthineers AG155.38bn13.91bn429.83bn68.70k30.853.1218.162.771.661.6618.5216.400.47693.674.44316,333.304.316.255.739.2537.2439.819.0310.030.679550.380.46--24.465.8522.325.659.71--
Data as of Aug 08 2022. Currency figures normalised to Coloplast A/S's reporting currency: Danish Krone DKK

Institutional shareholders

12.73%Per cent of shares held by top holders
HolderShares% Held
Fundsmith LLPas of 31 Dec 20216.61m3.34%
The Vanguard Group, Inc.as of 08 Jul 20223.63m1.83%
Norges Bank Investment Managementas of 31 Dec 20213.01m1.52%
Allianz Global Investors GmbHas of 30 Jun 20222.60m1.31%
BlackRock Fund Advisorsas of 07 Jul 20222.24m1.13%
Capital Research & Management Co. (World Investors)as of 30 Jun 20221.90m0.96%
Goodbody Stockbrokers ULC (Investment Management)as of 31 Dec 20211.72m0.87%
Geode Capital Management LLCas of 04 Aug 20221.28m0.64%
BlackRock Advisors (UK) Ltd.as of 07 Jul 20221.13m0.57%
Walter Scott & Partners Ltd.as of 08 Jul 20221.08m0.55%
More ▼
Data from 31 Dec 2021 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.